AP NEWS
ADVERTISEMENT
Press release content. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content
Press release content. The AP news staff was not involved in its creation.

GenScript Biotech Announces CE-IVD for Its Neutralizing Antibody Test Kit of SARS-CoV-2 and COVID-19 Diagnostic Products

May 26, 2020 GMT

LEIDEN, The Netherlands--(BUSINESS WIRE)--May 26, 2020--

GenScript Biotech Europe BV announced that it has obtained CE marking for its SARS-CoV-2 diagnostic products to be sold as an in vitro diagnostic (“IVD”). Among these products is the novel cPass TM – SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit which detects the presence of neutralizing antibodies in an hour and does not require live biological materials or biosafety containment for testing. This is a major advance in understanding the epidemiology of the disease and if individuals have developed neutralizing antibodies that may confer immunity.

ADVERTISEMENT

cPass TM - SARS-CoV-2 Surrogate Virus Neutralization test kit
The surrogate Virus Neutralization test kit is the result of an exclusive co-development agreement between Dr. Linfa Wang at Duke –NUS Medical School in Singapore, GenScript Biotech Corporation, and the Diagnostics Development Hub (DxD) at Singapore’s Agency for Science Technology and Research (A*STAR). Dr. Linfa Wang, a virologist, epidemiologist, and Director of the Emerging Infectious Disease program at Duke-NUS Medical School is one of the world’s leading experts on emerging zoonotic viruses. Dr. Wang serves on multiple World Health Organization (WHO) committees focused on COVID-19 and is the principal investigator of the collaboration.

GenScript went through the proof of concept research, product design, development, and optimization, working with Dr. Wang and the A*STAR team. GenScript now plays a central role in the commercialization process using its global network and manufacturing capabilities.

Dr. Wang said, “The cPass™Test Kit can be used for contact tracing, reservoir or intermediate animal tracking, assessment of herd immunity, the longevity of protective immunity and efficacy of different vaccine candidates. It does not require a biosafety containment facility, which makes it immediately accessible to the global community, including many developing nations”.

“Acquiring the CE-IVD mark expands the market opportunity for our detection kits in the EU and other major international markets,” said Patrick Liu, President of GenScript Biotech Europe BV. “I hope cPass™Test Kit will play a critical role in the global efforts of overcoming the pandemic.”

Together with the other CE-IVD tests GenScript offers including qRT-PCR detection kits and IgG & IgM serological testing kits, one can monitor the complete infection history of a person, from initial infection through the different stages of infection to the point of monitoring neutralizing antibodies as an indicator of future immunity against the virus.

ADVERTISEMENT

About GenScript
GenScript is a global biotechnology group providing gene, peptide, protein, CRISPR, and antibodies to scientists in more than 100 countries. Since its founding in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science and translational biomedical research, as well as early-stage pharmaceutical development. With a mission to improve the health of mankind and nature through biotechnology, the company has developed the best-in-class capacity and capability for producing biological reagents.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200526005189/en/

CONTACT: Jungsoo Park

jungsoo.park@genscript.com

KEYWORD: NETHERLANDS EUROPE

INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL DEVICES INFECTIOUS DISEASES HEALTH MEDICAL SUPPLIES

SOURCE: GenScript Biotech

Copyright Business Wire 2020.

PUB: 05/26/2020 09:00 AM/DISC: 05/26/2020 09:02 AM

http://www.businesswire.com/news/home/20200526005189/en

ADVERTISEMENT